BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price, Quote, News and Overview
NASDAQ:BDTX - Nasdaq - US09203E1055 - Common Stock - Currency: USD
BDTX Quote, Performance and Key Statistics
2.17
+0.06 (+2.84%)
The current stock price of BDTX is 2.17 USD. In the past month the price increased by 39.1%. In the past year, price decreased by -55.62%.
BDTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Related stock screener links
About BDTX
Company Profile
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Company Info
BLACK DIAMOND THERAPEUTICS I
One Main Street, 14th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: David M. Epstein
Employees: 24
Phone: 16174175868
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
What is the stock price of BLACK DIAMOND THERAPEUTICS I today?
The current stock price of BDTX is 2.17 USD. The price increased by 2.84% in the last trading session.
What is the ticker symbol for BLACK DIAMOND THERAPEUTICS I stock?
The exchange symbol of BLACK DIAMOND THERAPEUTICS I is BDTX and it is listed on the Nasdaq exchange.
On which exchange is BDTX stock listed?
BDTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BLACK DIAMOND THERAPEUTICS I stock?
11 analysts have analysed BDTX and the average price target is 13.26 USD. This implies a price increase of 511.06% is expected in the next year compared to the current price of 2.17. Check the BLACK DIAMOND THERAPEUTICS I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BLACK DIAMOND THERAPEUTICS I worth?
BLACK DIAMOND THERAPEUTICS I (BDTX) has a market capitalization of 123.00M USD. This makes BDTX a Micro Cap stock.
How many employees does BLACK DIAMOND THERAPEUTICS I have?
BLACK DIAMOND THERAPEUTICS I (BDTX) currently has 24 employees.
What are the support and resistance levels for BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
BLACK DIAMOND THERAPEUTICS I (BDTX) has a support level at 1.88 and a resistance level at 2.65. Check the full technical report for a detailed analysis of BDTX support and resistance levels.
Should I buy BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BDTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BDTX, evaluating the profitability, health, valuation and growth aspects
- BLACK DIAMOND THERAPEUTICS I (BDTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BLACK DIAMOND THERAPEUTICS I (BDTX) Sales and EPS estimates to see what analysts future expectations are.
- BLACK DIAMOND THERAPEUTICS I (BDTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BLACK DIAMOND THERAPEUTICS I (BDTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Chart to make your own analysis
- BLACK DIAMOND THERAPEUTICS I (BDTX) Latest news and press-releases to stay up to date.
Does BLACK DIAMOND THERAPEUTICS I (BDTX) stock pay dividends?
BDTX does not pay a dividend.
When does BLACK DIAMOND THERAPEUTICS I (BDTX) report earnings?
BLACK DIAMOND THERAPEUTICS I (BDTX) will report earnings on 2025-08-04, before the market open.
What is the Price/Earnings (PE) ratio of BLACK DIAMOND THERAPEUTICS I (BDTX)?
The PE ratio for BLACK DIAMOND THERAPEUTICS I (BDTX) is 36.17. This is based on the reported non-GAAP earnings per share of 0.06 and the current share price of 2.17 USD. Check the full fundamental report for a full analysis of the valuation metrics for BDTX.
What is the Short Interest ratio of BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
The outstanding short interest for BLACK DIAMOND THERAPEUTICS I (BDTX) is 17.2% of its float. Check the ownership tab for more information on the BDTX short interest.
BDTX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BDTX. When comparing the yearly performance of all stocks, BDTX is a bad performer in the overall market: 86.15% of all stocks are doing better.
BDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BDTX. While BDTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
BDTX Financial Highlights
Over the last trailing twelve months BDTX reported a non-GAAP Earnings per Share(EPS) of 0.06. The EPS increased by 103.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.81% | ||
| ROE | -83.66% | ||
| Debt/Equity | 0 |
BDTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to BDTX. The Buy consensus is the average rating of analysts ratings from 11 analysts.